Sensei Biotherapeutics Files 8-K
Ticker: SNSE · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials
TL;DR
Sensei Biotherapeutics filed a routine 8-K. No major news.
AI Summary
Sensei Biotherapeutics, Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial details or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Sensei Biotherapeutics is providing standard disclosures and financial information to the SEC, which is routine for public companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, not indicating any specific new risks or material adverse events.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- June 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-39980 (identifier) — Commission File Number
- 1405 Research Blvd, Suite 125 (address) — Principal Executive Offices
- Rockville, MD (location) — Principal Executive Offices
- 20850 (zip_code) — Principal Executive Offices
- (240) 243-8000 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Sensei Biotherapeutics, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 3, 2024.
In which state is Sensei Biotherapeutics, Inc. incorporated?
Sensei Biotherapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Sensei Biotherapeutics, Inc.?
The principal executive office address is 1405 Research Blvd, Suite 125, Rockville, MD 20850.
What is the Commission File Number for Sensei Biotherapeutics, Inc.?
The Commission File Number for Sensei Biotherapeutics, Inc. is 001-39980.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-03 07:31:03
Filing Documents
- d845171d8k.htm (8-K) — 26KB
- d845171dex991.htm (EX-99.1) — 54KB
- g845171ex99_1s10g1.jpg (GRAPHIC) — 118KB
- g845171ex99_1s11g1.jpg (GRAPHIC) — 113KB
- g845171ex99_1s12g1.jpg (GRAPHIC) — 104KB
- g845171ex99_1s13g1.jpg (GRAPHIC) — 116KB
- g845171ex99_1s14g1.jpg (GRAPHIC) — 92KB
- g845171ex99_1s15g1.jpg (GRAPHIC) — 95KB
- g845171ex99_1s16g1.jpg (GRAPHIC) — 132KB
- g845171ex99_1s17g1.jpg (GRAPHIC) — 83KB
- g845171ex99_1s18g1.jpg (GRAPHIC) — 143KB
- g845171ex99_1s19g1.jpg (GRAPHIC) — 132KB
- g845171ex99_1s1g1.jpg (GRAPHIC) — 96KB
- g845171ex99_1s20g1.jpg (GRAPHIC) — 117KB
- g845171ex99_1s21g1.jpg (GRAPHIC) — 86KB
- g845171ex99_1s22g1.jpg (GRAPHIC) — 111KB
- g845171ex99_1s23g1.jpg (GRAPHIC) — 103KB
- g845171ex99_1s24g1.jpg (GRAPHIC) — 130KB
- g845171ex99_1s25g1.jpg (GRAPHIC) — 147KB
- g845171ex99_1s26g1.jpg (GRAPHIC) — 112KB
- g845171ex99_1s27g1.jpg (GRAPHIC) — 139KB
- g845171ex99_1s28g1.jpg (GRAPHIC) — 93KB
- g845171ex99_1s29g1.jpg (GRAPHIC) — 84KB
- g845171ex99_1s2g1.jpg (GRAPHIC) — 206KB
- g845171ex99_1s30g1.jpg (GRAPHIC) — 128KB
- g845171ex99_1s31g1.jpg (GRAPHIC) — 96KB
- g845171ex99_1s32g1.jpg (GRAPHIC) — 86KB
- g845171ex99_1s33g1.jpg (GRAPHIC) — 102KB
- g845171ex99_1s34g1.jpg (GRAPHIC) — 85KB
- g845171ex99_1s35g1.jpg (GRAPHIC) — 94KB
- g845171ex99_1s36g1.jpg (GRAPHIC) — 98KB
- g845171ex99_1s37g1.jpg (GRAPHIC) — 103KB
- g845171ex99_1s38g1.jpg (GRAPHIC) — 91KB
- g845171ex99_1s39g1.jpg (GRAPHIC) — 121KB
- g845171ex99_1s3g1.jpg (GRAPHIC) — 105KB
- g845171ex99_1s40g1.jpg (GRAPHIC) — 28KB
- g845171ex99_1s41g1.jpg (GRAPHIC) — 64KB
- g845171ex99_1s42g1.jpg (GRAPHIC) — 138KB
- g845171ex99_1s43g1.jpg (GRAPHIC) — 122KB
- g845171ex99_1s44g1.jpg (GRAPHIC) — 91KB
- g845171ex99_1s45g1.jpg (GRAPHIC) — 104KB
- g845171ex99_1s46g1.jpg (GRAPHIC) — 111KB
- g845171ex99_1s47g1.jpg (GRAPHIC) — 74KB
- g845171ex99_1s48g1.jpg (GRAPHIC) — 98KB
- g845171ex99_1s49g1.jpg (GRAPHIC) — 121KB
- g845171ex99_1s4g1.jpg (GRAPHIC) — 93KB
- g845171ex99_1s50g1.jpg (GRAPHIC) — 107KB
- g845171ex99_1s5g1.jpg (GRAPHIC) — 105KB
- g845171ex99_1s6g1.jpg (GRAPHIC) — 107KB
- g845171ex99_1s7g1.jpg (GRAPHIC) — 117KB
- g845171ex99_1s8g1.jpg (GRAPHIC) — 90KB
- g845171ex99_1s9g1.jpg (GRAPHIC) — 83KB
- 0001193125-24-152363.txt ( ) — 7588KB
- snse-20240603.xsd (EX-101.SCH) — 4KB
- snse-20240603_def.xml (EX-101.DEF) — 14KB
- snse-20240603_lab.xml (EX-101.LAB) — 23KB
- snse-20240603_pre.xml (EX-101.PRE) — 15KB
- d845171d8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: June 3, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3